Psychopharmacology of Psilocybin in Cancer Patients
Randomised, quadruple-blind, crossover trial (n=56) in adults with cancer-related anxiety/depressive symptoms testing two oral psilocybin sessions (low vs high dose) as supportive care.
Details
This supportive-care study evaluates whether psilocybin can produce personally and spiritually meaningful experiences and reduce anxiety/depressive symptoms in patients with life-threatening cancer diagnoses.
Participants (21–80 years; ECOG 0–2) complete two monitored oral psilocybin sessions in a randomised, quadruple-blind, crossover sequence comparing low and high doses; outcomes include mood, anxiety, and coping.
Key exclusions include major cardiovascular, hepatic, renal, or neurological disease; contraindicated medications; severe psychiatric comorbidity; and family history of psychosis or bipolar disorder.